1,484 results on '"Porter, David L."'
Search Results
2. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
3. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
4. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel
5. Seeds of a Different Eden: Chinese Gardening Ideas and a New English Aesthetic Ideal (review)
6. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines
7. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells
8. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
9. Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
10. Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells
11. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
12. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
13. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
14. Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy
15. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies
16. Impact of late immune effector cell associated hematotoxicity (ICAHT) and prolonged neutropenia after CAR-T therapy on infection and survival outcomes.
17. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia
18. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy
19. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
20. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas
21. Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with Myelofibrosis
22. Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting
23. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
24. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
25. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
26. CAR T Toxicity Management: Cytokine Release Syndrome and Neurotoxicity
27. CAR T Cells for Hematologic Malignancies
28. Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients
29. TET2 regulates early and late transitions in exhausted CD8+T-cell differentiation and limits CAR T-cell function
30. CAR T-Cell Immunotherapy in Minority Patients with Lymphoma
31. Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma
32. Interim Results of a Phase I/II Trial of Intermediate-Dose Post-Transplantation Cyclophosphamide after Reduced Intensity Conditioned HLA-Mismatched Bone Marrow Transplantation for Older or Unfit Patients
33. Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel: A Cell Therapy Consortium Study
34. Post-Transplant Frailty Phenotype Predicts Survival
35. Risk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study
36. One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant.
37. Author Correction: Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
38. Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children
39. Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic
40. Past and Future Reflections and Profiles of a Pioneer
41. Bendamustine Lymphodepletion Before Axicabtagene Ciloleucel Is Safe and Associates with Reduced Inflammatory Cytokines
42. Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation
43. Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma
44. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration
45. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy
46. Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation.
47. Deletion of the inhibitory co-receptor CTLA4 enhances and invigorates chimeric antigen receptor T cells
48. One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant
49. Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors
50. Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.